Media headlines about Lumenis (NASDAQ:LMNS) have been trending positive on Friday, according to Accern Sentiment. Accern rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Lumenis earned a coverage optimism score of 0.32 on Accern’s scale. Accern also assigned media coverage about the medical equipment provider an impact score of 50.7747145316948 out of 100, indicating that recent press coverage is somewhat likely to have an impact on the stock’s share price in the near future.

Lumenis Company Profile

Lumenis Ltd. (Lumenis) is a provider of energy-based, minimally invasive clinical solutions. The Company operates through three segments: surgical, ophthalmic and aesthetic. The Company offers energy-based solutions for medically necessary and elective procedures, primarily for the aging population. Its solutions include the holmium laser, the Lumenis Pulse 120H, used for urologic applications; the VersaPulse PowerSuite platform which uses holmium lasers for urologic applications; the M22 multi-energy, a multi-application platform for the treatment of various skin conditions, and the Selecta multi-modality platform for retinal, secondary cataract and glaucoma therapies.

Recommended Story: Google Finance Portfolio Tips and Tricks

Insider Buying and Selling by Quarter for Lumenis (NASDAQ:LMNS)

Receive News & Ratings for Lumenis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lumenis and related companies with MarketBeat.com's FREE daily email newsletter.